Full Product Name
C8B siRNA (Human)
Product Synonym Names
Complement component C8 beta chain; Complement component 8 subunit beta
Product Gene Name
C8B sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for P07358
Specificity
C8B siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human C8B gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of C8B sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
C8B sirna
siRNA to inhibit C8B expression using RNA interference
Applications Tested/Suitable for C8B sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for C8B. It may not necessarily be applicable to this product.
NCBI Accession #
NP_000057.2
[Other Products]
NCBI GenBank Nucleotide #
NM_000066.3
[Other Products]
UniProt Primary Accession #
P07358
[Other Products]
UniProt Secondary Accession #
A1L4K7[Other Products]
UniProt Related Accession #
P07358[Other Products]
Molecular Weight
67,047 Da
NCBI Official Full Name
complement component C8 beta chain isoform 1 preproprotein
NCBI Official Synonym Full Names
complement component 8, beta polypeptide
NCBI Official Symbol
C8B??[Similar Products]
NCBI Official Synonym Symbols
C82
??[Similar Products]
NCBI Protein Information
complement component C8 beta chain
UniProt Protein Name
Complement component C8 beta chain
UniProt Synonym Protein Names
Complement component 8 subunit beta
Protein Family
Complement component
UniProt Gene Name
C8B??[Similar Products]
UniProt Entry Name
CO8B_HUMAN
NCBI Summary for C8B
This gene encodes one of the three subunits of the complement component 8 (C8) protein. C8 is composed of equimolar amounts of alpha, beta and gamma subunits, which are encoded by three separate genes. C8 is one component of the membrane attack complex, which mediates cell lysis, and it initiates membrane penetration of the complex. This protein mediates the interaction of C8 with the C5b-7 membrane attack complex precursor. In humans deficiency of this protein is associated with increased risk of meningococcal infections. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jun 2013]
UniProt Comments for C8B
C8B: Constituent of the membrane attack complex (MAC) that plays a key role in the innate and adaptive immune response by forming pores in the plasma membrane of target cells. Defects in C8B are a cause of complement component 8 deficiency type 2 (C8D2). A rare defect of the complement classical pathway associated with susceptibility to severe recurrent infections, predominantly by Neisseria gonorrhoeae or Neisseria meningitidis. Belongs to the complement C6/C7/C8/C9 family.
Protein type: Secreted; Secreted, signal peptide
Chromosomal Location of Human Ortholog: 1p32.2
Cellular Component: membrane attack complex; extracellular space; membrane; extracellular region; vesicle
Molecular Function: protein complex binding
Biological Process: cytolysis; complement activation, alternative pathway; regulation of complement activation; innate immune response; immune response; complement activation, classical pathway; complement activation
Disease: Complement Component 8 Deficiency, Type Ii
Research Articles on C8B
1. Observational study of gene-disease association and gene-gene interaction. (HuGE Navigator)
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
